Adjuvant tamoxifen and chemotherapy in stage II breast cancer: Interim findings from NSABP protocol B‐09

Publisher Website
Google Scholar
Abstract
Data are presented from a prospective clinical trial in which 1,891 patients with histologically confirmed stage II breast cancer were randomized to receive adjuvant therapy consisting of 1‐phenylalanine mustard and 5‐fluorouracil (PF) with and without tamoxifen (T). The findings indicate that the benefit previously noted for the addition of tamoxifen at 2 and 3 years' mean follow‐up is still apparent at 4 years. Although the tamoxifen‐containing regimen prolongs disease‐free survival and survival, this effect is not uniform and is dependent on patient age and tumor receptor content. Only those patients ⩾ 50 years of age demonstrated a benefit from the addition of tamoxifen to chemotherapy. The benefit was influenced by the degree of quantitative tumor receptor content. Patients ⩽ 49 years of age failed to demonstrate a prolongation in disease‐free survival with tamoxifen even when the tumor estrogen receptor content was ⩾100 fmol. Not only was there no benefit attributable to tamoxifen in patients ⩽49 years, if the tumor progesterone receptors were .
Funding Information
  • American Cancer Society (ACS-RC-13)

This publication has 7 references indexed in Scilit: